Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Clinical Trial

Business briefs: Actavis, Bayer, Oramed, Elan

May 20, 2013

Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M
 

Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity

May 09, 2013

HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
 

Business briefs: Baxter; Eli Lilly; CDHPs and Statins

May 07, 2013

Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.
 

FDA streamlines patient access information

May 06, 2013

A new FDA site gives patients a one-stop shop for commenting on pending regulations, finding clinical trials and navigating treatment options.
 

BMS scores "breakthrough" label for hep. C candidate

April 25, 2013

The regulatory coup means BMS gets to work with FDA to develop its home-grown hep. C cocktail, which is on a competitive track to another hep. C alliance with Merck.
 

Business Briefs: Docs question Gleevec price, Sanofi pill may delay MS onset

April 25, 2013

Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital.
 

After Q1 sales slip, GSK seeks to reassure investors

April 24, 2013

CEO Andrew Witty said the quarter's results were what the company expected.
 

Higher prices keep Lilly's quarter flat; Cymbalta DTC pull-back planned

April 24, 2013

Lilly said sales-force downsizing was the right move considering the current portfolio mix and generics shadow. Management also teased some vague pipeline details.
 

Data show Gilead's sofosbuvir has 'clean' safety profile

April 24, 2013

Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.
 

Business Briefs: GSK, Astellas, Vertex and Orexigen

April 22, 2013

GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.
 

Consumers Must Make Own Choices as Health Guidelines Change

Nancy Hicks April 19, 2013

Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.
 

Lilly digs deeper into Alzheimer's

April 17, 2013

The company has licensed two tracers that will be used in its anti-amyloid and anti-tau research, and its still-breathing solanezumab binds to beta-amyloid proteins
 

Business briefs: GlaxoSmithKline, Adverse Event reporting, Elan

April 15, 2013

GSK's Avandia woes continue, study finds a new way to identify adverse events, and Royalty ups its bid for Elan.
 

Rare disease awareness fails to ease physician, patient burden

April 15, 2013

A study shows FDA approvals and awareness efforts are having little impact on physician awareness or patient frustration.
 

Pfizer pipeline breast cancer drug gets fast tracked

April 11, 2013

FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs.
 

Business briefs: Roche, Vital Art and Science, Gilead, Sanofi

April 09, 2013

Roche and Isis pair up for Huntingtons, Vital's prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi's emerging market exposure grabs attention.
 

AstraZeneca RA drug logs unimpressive PHIII results

April 08, 2013

The drug maker's oral SYK inhibitor delivered good news-bad news Phase III fostamatinib results Friday.
 

Business briefs: Walgreens; Pfizer; Roche

April 04, 2013

Walgreens retail clinics expand diagnostic services, Pfizer says OTC is staying put, Roche-BMS melanoma drug mix runs into PHI troubles.
 

Business briefs: AstraZeneca, Everyday Health, J&J

April 02, 2013

AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales
 

Business briefs: Biogen Idec; Novo Nordisk and Merrion; Pfizer; FDA; inVentiv Health

March 20, 2013

Biogen's MS oral hopeful gets extra patent life; Novo's novel oral insulin passes Phase I; Pfizer gets clinical research equivalent of Good Housekeeping stamp of approval; FDA's acting generics chief; InVentiv buys stake in an electronic clinical trial company
 

Business briefs: HRT, HPV, Novo Nordisk

March 18, 2013

Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
 

Business briefs: Merck, Shire

March 12, 2013

Merck's Vytorin trial rolls on, Shire expands into neonatology
 

Business briefs: Lundbeck, FDA, Tower Watson and National Business Group Study, Merck

March 07, 2013

Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief
 

Janu-"Meh": pancreatitis study fails to cause uproar

March 05, 2013

A study linking higher levels of hospitalizing pancreatitis among Januvia and Byetta patients has not caused a patient backlash.
 

Rare disease awareness more than just a day for pharmas

February 28, 2013

Industry observances of Rare Disease Awareness Day are getting more elaborate of late—perhaps not solely for altruistic reasons, as a third of NMEs approved by FDA over the past five years were for the treatment of rare diseases.
 

Business briefs: Gilead, Shire, The Medicines Co., HHS

February 04, 2013

HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
 

CMS releases "Sunshine" final rule: federal preemption, August start date

February 01, 2013

CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
 

Researcher takes aim at clashing drug data

January 31, 2013

An expert witness in a 2008 lawsuit highlights holes in clinical data, and finds that corporate and published trial data do not necessarily correspond.
 

Business briefs: Boston Scientific, Eli Lilly, Genzyme

January 29, 2013

Boston Scientific to slash around 1,000 jobs, Lilly exited 2012 7% lighter on sales, Genzyme is seeking a new indication for Lemtrada.
 

Orexigen rethinks clinical trial recruitment

January 24, 2013

Orexigen slashed its clinical trial recruitment period by 14 months using marketing tactics associated with retail.
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising App Approval Clinical Trial Consumer COPD Corporate Reputation Diabetes DTC Earnings FDA Generic Generic Drugs Health Affairs iPad Marketing & Communications Merck Mobile Obesity Patent Cliff Patients Regulatory Wellness